Biovie.
French company founded in 2007, specializing in online sales of organic, raw, and living foods, committed to education on healthy eating.
- Reports this week
- 0
- Active events
- 0
- Connections
- 38
What's happening
Earlier this month
One to three months ago
-
Biovie discussed Phase 2 results for its bezisterim treatment and ongoing development of new antibiotics for difficult infections.Some support2 reports
-
BioVie's candidate outperformed findings from an initiative led by the National Institutes of Health.Some support1 report
-
BioVie is seeking pivotal milestones for its lead drug candidate targeting neuroinflammation pathways for Parkinson's disease.Well supported3 reports
-
BioVie Inc., led by Cuong Do, is listed on Nasdaq, while First Phosphate, led by Passalacqua, is building a North American supply chain with European interest.Some support1 report
-
MarketBeat's screener tool lists BioVie as a penny stock.Some support1 report
-
Biovie submitted trial data to the U.S. Food and Drug Administration and announced results from its offices in Carson City, Nev.Some support2 reports
Gone quiet
No new reports in 90+ days-
BioVie is testing a drug candidate called bezisterim for Long COVID and has received funding from the U.S. Department of Defense.Some support1 report
-
Mark Stacy was listed as an author on a clinical trial poster for Biovie.Speculative1 report
-
Biovie presented data at a conference held in Rome on July 24, 2025.Some support2 reports
-
Cuong Do was named CEO of Biovie, while FLOKI debuted a commercial broadcast by Bloomberg Television.Some support3 reports
-
Vision Marine Technologies Inc. filed a registration statement with the SEC, with ThinkEquity acting as the sole book-running manager.Some support3 reports
-
CDC reported that 6.9% of U.S. adults have long COVID, and the ADDRESS-LC trial is enrolling patients.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Biovie this week
News at the entities that move Biovie most-
Nasdaq StructuralUnicycive Therapeutics, Inc. is facing investigator findings regarding manufacturing compliance issues from the FDA.Moves Biovie
-
FDA StructuralOEHHA is questioning the FDA regarding the safety levels of dyes.Moves Biovie
-
MarketBeat Mentioned togetherMarketBeat released analyst recommendations for small-cap communication services companies Optimum Communications and Criteo.Moves Biovie
-
Securities and Exchange Commission StructuralSGCV audited HDPI's financial statements, which were subsequently filed with the Securities and Exchange Commission in the Philippines.Moves Biovie
-
National Institutes of Health OperationalThe Trump administration seeks greater control over NIH grantmaking, while Susan Collins objects to the Office of Management and Budget's involvement.Moves Biovie
-
Bloomberg Television OperationalNew to The Street launched a commercial campaign for Synergy CHC utilizing Bloomberg Television in New York City.Moves Biovie
Connections
The 16 strongest of 38, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Nasdaq Structural
Biovie Inc. is a company whose shares are formally listed and traded on the Nasdaq stock exchange.
-
Cuong Do Structural
Cuong Do holds the executive leadership role of President and CEO at Biovie.
-
FDA Structural
Biovie relies on the FDA's regulatory review process for drug development and seeking approval.
-
Renaissance Technologies Transactional
Renaissance Technologies increased its financial holdings and stake in Biovie stock.
-
Mark Stacy Operational
Mark Stacy is a professional contributor whose expertise is featured in company trials and presentations for Biovie.
-
MarketBeat Mentioned together
MarketBeat tracks and reports on Biovie's market status, and Biovie utilizes MarketBeat's consensus rating data.
-
Bloomberg Television Operational
Biovie leverages Bloomberg Television as a platform to broadcast its innovations and clinical results.
-
Securities and Exchange Commission Structural
Biovie is subject to regulatory oversight by the SEC, requiring the filing of insider transactions.
Show all 16 connections
-
National Institutes of Health Operational
Biovie's candidate was evaluated against and found to outperform findings from the NIH initiative.
-
phase Operational
Biovie is actively conducting a Phase IIb clinical trial.
-
North America Shared context
Biovie conducts clinical trials and advances its pipeline within the North American market context.
-
New York City Shared context
Biovie conducts professional activities and broadcasts while located in New York City.
-
San Francisco Shared context
The company is contextually linked to the city through the presence of associated medical professionals.
-
San Diego Shared context
Biovie conducted a clinical meeting within the geographic context of San Diego.
-
Latin America Shared context
Biovie is featured in a broadcast that covers the Latin America region.
-
Carson City Shared context
Biovie maintains offices in Carson City, Nevada.
History
Events by the month they beganSeptember 2026
2 eventsAugust 2026
3 events- BioVie Inc., led by Cuong Do, is listed on Nasdaq, while First Phosphate, led by Passalacqua, is building a North American supply chain with European interest.
- MarketBeat's screener tool lists BioVie as a penny stock.
- Biovie submitted trial data to the U.S. Food and Drug Administration and announced results from its offices in Carson City, Nev.
June 2026
8 events- BioVie Inc. shares are traded on Nasdaq, and MarketBeat reported its average stock rating.
- BioVie is seeking pivotal milestones for its lead drug candidate targeting neuroinflammation pathways for Parkinson's disease.
- BioVie is testing a drug candidate called bezisterim for Long COVID and has received funding from the U.S. Department of Defense.
- Mark Stacy was listed as an author on a clinical trial poster for Biovie.
- Biovie presented data at a conference held in Rome on July 24, 2025.
- Cuong Do was named CEO of Biovie, while FLOKI debuted a commercial broadcast by Bloomberg Television.
- Vision Marine Technologies Inc. filed a registration statement with the SEC, with ThinkEquity acting as the sole book-running manager.
- CDC reported that 6.9% of U.S. adults have long COVID, and the ADDRESS-LC trial is enrolling patients.